UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000046586
Receipt number R000053041
Scientific Title A preliminary study on the effect of a lactic acid bacteria intake on immune function. -a open-label, single-arm trial-
Date of disclosure of the study information 2022/01/19
Last modified on 2022/08/09 11:12:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A preliminary study on the effect of a lactic acid bacteria intake on immune function. -a open-label, single-arm trial-

Acronym

A preliminary study on the effect of a lactic acid bacteria intake on immune function

Scientific Title

A preliminary study on the effect of a lactic acid bacteria intake on immune function. -a open-label, single-arm trial-

Scientific Title:Acronym

A preliminary study on the effect of a lactic acid bacteria intake on immune function

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to investigate the effect of continuous intake of a hard capsule containing killed lactic acid bacteria powder for 8 weeks on immune function in healthy males and females aged between 40 and less than 65 years old.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Immune function-related markers
Questionnaire for physical health
Questionnaire for fatigue assessment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Take one capsule of the test food with water or warm water within 30 min after dinner once a day.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1. Aged between 40 and less than 65 years old.
2. Japanese males and females.
3. Individuals who contract the common cold between winter and spring every year.
4. BMI between 18.5 kg/m^2 and less than 30.0 kg/m^2.
5. Individuals who can use smartphones or PCs to input an electronic diary.
6. Individuals who received sufficient explanation for the objective and summary of the trial, and voluntarily volunteered to the trial with the agreement of informed consent.

Key exclusion criteria

1. Individuals who have mouth dryness, or Sjogren's syndrome.
2. Individuals who are currently undergoing treatment for any disease.
3. Individuals who have been receiving nutritional and exercise therapy under medical doctor's management.
4. Individuals who have severe diseases or a history of severe diseases.
5. Individuals who have allergic dermatitis, allergic rhinitis, bronchial asthma, or chronic bronchitis.
6. Individuals who have currently been taking commercially available drugs, quasi-drug products, and foods, drinks, or supplements with any functional claims.
7. Individuals who have been taking yogurts, beverages, health foods, supplements which include lactic acid bacteria and/or Bifidobacterium.
8. Individuals who have a drug allergy, or a food allergy.
9. Individuals who are currently pregnant or breastfeeding, or planning to pregnant during the study period.
10. Individuals who work in shift and night shift.
11. Individuals who are planning travel to foreign countries during the study period.
12. Individuals who drink more than 60 g alcohol/day.
13. Individuals who have been vaccinated to protect against infectious diseases, such as influenza virus or SARS-CoV-2, one month before the screening period. Also, individuals who are planning vaccination during the study period.
14. Individuals who are planning extremely change their lifestyle (such as diet, sleep, or exercise) during the study period.
15. Individuals who joined other clinical trials from one month before obtaining informed consent in this study, or individuals who have currently been joined other clinical trials. Also, individuals who are planning to join other clinical trials.
16. Individuals who are unsuitable for this study, that judged by the principal investigator.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Eriko
Middle name
Last name Uehara

Organization

Sanwa Shurui Co., Ltd.

Division name

Research & Development Laboratory

Zip code

879-0495

Address

2231-1 Yamamoto, Usa, Oita,879-0495

TEL

0978-33-3844

Email

dobashi-e@kokuzo.co.jp


Public contact

Name of contact person

1st name Yoshitada
Middle name
Last name Hira

Organization

IMEQRD Co., Ltd.

Division name

Sales department

Zip code

104-0061

Address

Daiwa Ginza Bld. 3F, 6-2-1, Ginza, Chuo-ku

TEL

03-6704-5968

Homepage URL


Email

y-hira@imeqrd.co.jp


Sponsor or person

Institute

IMEQRD Co., Ltd

Institute

Department

Personal name



Funding Source

Organization

Sanwa Shurui Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Suda Clinic institutional review board

Address

2-8-14,Takadanobaba,Shinjyuku,Tokyo

Tel

03-6704-5968

Email

n-yuzawa@imeqrd.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 01 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

20

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 10 Month 12 Day

Date of IRB

2021 Year 12 Month 21 Day

Anticipated trial start date

2022 Year 01 Month 21 Day

Last follow-up date

2022 Year 03 Month 18 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 01 Month 07 Day

Last modified on

2022 Year 08 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053041


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name